Viatris has outlined plans to reduce its global workforce by about 10% over the next three years after completing an enterprise-wide strategic review launched in 2025. The announcement was made in conjunction with updates regarding its manufacturing network in India, where the company has been addressing regulatory action at one facility and managing the aftermath of a recent fire at another plant.
In its fourth-quarter and full-year earnings release, Viatris stated that it anticipates recording restructuring-related charges totaling between $700 million and $850 million. The company said these expenses will consist of inventory write-offs, severance payments, contract terminations, vendor consolidations, and other network modernization costs.
Once the restructuring initiative has been fully executed, Viatris projects annual cost savings in the range of $600 million to $700 million. According to the company, most of these savings are expected to support operating cash flow.
The planned reductions are expected to affect a range of departments across the organization. Areas identified include commercial teams, research and development, medical affairs, and manufacturing operations. As of last year, Viatris reported a global workforce of 32,000 employees. A reduction of roughly 10% would correspond to as many as 3,000 positions. The company indicated that the majority of the workforce changes are expected to be implemented over the coming three years.
Headquartered in the United States, Viatris maintains global centers in Pittsburgh, Shanghai, and Hyderabad, India. The company operates across more than 165 countries and territories, according to a November filing with the U.S. Securities and Exchange Commission, and reports having more than 30,000 employees in that disclosure.
In India, Viatris has spent more than a year working to resolve concerns raised by the U.S. Food and Drug Administration at its manufacturing plant in Indore. The FDA issued a warning letter and placed the facility on import alert in late 2024. In an update provided last month, the company said it had “substantially completed remediation” at the site and that it is awaiting a reinspection by the agency.
The regulatory measures connected to the Indore plant had a financial impact during the previous year. Viatris reported that the FDA’s action resulted in approximately $370 million in lost revenue. In a related investor presentation, the company stated that it expects a partial supply recovery from the facility to provide a financial tailwind for the year.
Separately, Viatris disclosed that a fire broke out in mid-February in a service area at its oral solid dose manufacturing facility in Nashik, India. Following the incident, manufacturing activities at the site were temporarily suspended. The company said it anticipates resuming production in April and expects operations to restart roughly two months after the fire occurred.
For the full year, Viatris reported global sales of $14.3 billion, representing a 3% decline compared with 2024. Looking ahead, the company forecasts that revenue in 2026 will range between $14.45 billion and $14.95 billion, based on its current outlook.
Viatris Announces Workforce Cuts After Strategic Review
Viatris, the global healthcare company, is moving forward with a major restructuring that includes cutting up to 10% of its worldwide workforce after completing an enterprise-wide strategic review. The plan, announced in February 2026, is part of a broader effort to streamline operations and realize cost savings over the next three years.
Strategic Review Spurs Cost Reduction
Following a strategic review that began in 2025, Viatris determined that restructuring was necessary to improve efficiency and adapt to shifting market conditions. The job cuts are expected to primarily affect functions across commercial teams, R&D, medical affairs, manufacturing, and supply chain operations.
With a global workforce of over 30,000 employees, Viatris could see approximately 3,000 positions affected by the cuts. Management projects significant annual cost savings once the restructuring is complete, enabling the company to invest in core business areas and sustain long-term growth.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
